Roche's Co-Exclusive License for PI3K Marker Will Aid in Personalization of Genentech Drugs | GenomeWeb

In obtaining a license for the PI3K biomarker, Roche plans to investigate at least two investigational oncology drugs with a pharmacogenomic strategy.

Roche announced this week that it has acquired a co-exclusive license for the biomarker from Qiagen. Johns Hopkins University, which owns the patent for the PI3K marker, granted an exclusive license to Qiagen's DxS subsidiary in February.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.